Non-Current Liabilities
Contingent Consideration Liability (Non-Current)
Incyte Contingent Consideration Liability (Non-Current) decreased by 11.6% to $70.62M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 53.9%, from $153.28M to $70.62M. Over 5 years (FY 2020 to FY 2025), Contingent Consideration Liability (Non-Current) shows a downward trend with a -18.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ2 2016
Last reportedQ1 2026Apr 28, 2026
How to read this metric
Changes reflect updates to the probability of achieving milestones; an increase may signal higher confidence in drug development success.
Detailed definition
The estimated fair value of future payments owed to sellers in business combinations, contingent upon the achievement of...
Peer comparison
Specific to R&D-heavy industries like biotech where acquisitions often include earn-outs based on clinical trial outcomes.
Metric ID:
contingent_consideration_liability_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $219.01M | $213.78M | $206.99M | $204.13M | $200.09M | $171.81M | $184.46M | $180.83M | $179.49M | $170.19M | $173.58M | $164.84M | $156.85M | $166.67M | $153.76M | $153.28M | $160.16M | $138.38M | $79.86M | $70.62M |
| QoQ Change | — | -2.4% | -3.2% | -1.4% | -2.0% | -14.1% | +7.4% | -2.0% | -0.7% | -5.2% | +2.0% | -5.0% | -4.9% | +6.3% | -7.7% | -0.3% | +4.5% | -13.6% | -42.3% | -11.6% |
| YoY Change | — | — | — | — | -8.6% | -19.6% | -10.9% | -11.4% | -10.3% | -0.9% | -5.9% | -8.8% | -12.6% | -2.1% | -11.4% | -7.0% | +2.1% | -17.0% | -48.1% | -53.9% |
Range$70.62M – $219.01M
CAGR-21.2%
Avg YoY Growth-14.2%
Median YoY Growth-10.6%
Current Streak3 quarters decline
Contingent Consideration Liability (Non-Current) at Other Companies
Frequently Asked Questions
- What is Incyte's contingent consideration liability (non-current)?
- Incyte (INCY) reported contingent consideration liability (non-current) of $70.62M in Q1 2026.
- How has Incyte's contingent consideration liability (non-current) changed year-over-year?
- Incyte's contingent consideration liability (non-current) decreased by 53.9% year-over-year, from $153.28M to $70.62M.
- What is the long-term trend for Incyte's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Incyte's contingent consideration liability (non-current) has grown at a -18.9% compound annual growth rate (CAGR), from $227.6M to $79.86M.
- What does contingent consideration liability (non-current) mean?
- Long-term debt owed to sellers of acquired companies if certain future goals are met.